JP2024081668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024081668A5 JP2024081668A5 JP2024034617A JP2024034617A JP2024081668A5 JP 2024081668 A5 JP2024081668 A5 JP 2024081668A5 JP 2024034617 A JP2024034617 A JP 2024034617A JP 2024034617 A JP2024034617 A JP 2024034617A JP 2024081668 A5 JP2024081668 A5 JP 2024081668A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- indicates
- antisense strand
- rnai oligonucleotide
- ome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061676P | 2020-08-05 | 2020-08-05 | |
| US63/061,676 | 2020-08-05 | ||
| US202063074779P | 2020-09-04 | 2020-09-04 | |
| US63/074,779 | 2020-09-04 | ||
| JP2023507767A JP7476422B2 (ja) | 2020-08-05 | 2021-08-05 | Ｌｐａ発現を阻害するための組成物及び方法 |
| PCT/US2021/071109 WO2022032288A1 (en) | 2020-08-05 | 2021-08-05 | Compositions and methods for inhibiting lpa expression |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507767A Division JP7476422B2 (ja) | 2020-08-05 | 2021-08-05 | Ｌｐａ発現を阻害するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024081668A JP2024081668A (ja) | 2024-06-18 |
| JP2024081668A5 true JP2024081668A5 (enExample) | 2024-08-13 |
Family
ID=77519885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507767A Active JP7476422B2 (ja) | 2020-08-05 | 2021-08-05 | Ｌｐａ発現を阻害するための組成物及び方法 |
| JP2024034617A Pending JP2024081668A (ja) | 2020-08-05 | 2024-03-07 | Ｌｐａ発現を阻害するための組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507767A Active JP7476422B2 (ja) | 2020-08-05 | 2021-08-05 | Ｌｐａ発現を阻害するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12435336B2 (enExample) |
| EP (1) | EP4192954A1 (enExample) |
| JP (2) | JP7476422B2 (enExample) |
| KR (2) | KR20250077604A (enExample) |
| CN (1) | CN116323943A (enExample) |
| AU (2) | AU2021320550B2 (enExample) |
| BR (1) | BR112023001957A2 (enExample) |
| CA (1) | CA3185348A1 (enExample) |
| IL (1) | IL300338A (enExample) |
| MX (1) | MX2023001538A (enExample) |
| TW (2) | TWI886314B (enExample) |
| WO (1) | WO2022032288A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250077604A (ko) | 2020-08-05 | 2025-05-30 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
| US20250332190A1 (en) * | 2021-12-16 | 2025-10-30 | Tuojie Biotech (Shanghai) Co., Ltd. | Lpa-targeting sirna and conjugate |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| AR129073A1 (es) * | 2022-04-15 | 2024-07-10 | Dicerna Pharmaceuticals Inc | Composiciones y métodos para modular la actividad de scap |
| AU2023321619A1 (en) * | 2022-08-11 | 2025-03-06 | Sirius Therapeutics, Inc. | Polynucleic acid molecules for inhibiting expression of lp(a), pharmaceutical compositions, and uses thereof |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| EP4622983A1 (en) | 2022-11-23 | 2025-10-01 | Eli Lilly and Company | Method of synthesizing 4'-phosphate analog nucleotide phosphoramidite |
| AU2023384015A1 (en) | 2022-11-23 | 2025-05-22 | Eli Lilly And Company | Methods of synthesizing a targeting ligand-conjugated nucleotide phosphoramidite |
| WO2024137622A1 (en) | 2022-12-22 | 2024-06-27 | Eli Lilly And Company | Oligonucleotide fragments and methods of making rnai agents using the same |
| IL321855A (en) | 2023-01-13 | 2025-08-01 | Lilly Co Eli | Pharmaceutical preparations containing therapeutic oligonucleotides and dosage regimens using the same |
| WO2024197065A2 (en) * | 2023-03-20 | 2024-09-26 | Verve Therapeutics, Inc. | In vivo nickase-based editing of the lpa gene for treatment of cardiovascular disease |
| CN118685405A (zh) * | 2023-06-20 | 2024-09-24 | 施能康医药科技(苏州)有限公司 | 靶向脂蛋白a的核酸及其用途 |
| TW202530406A (zh) | 2023-09-21 | 2025-08-01 | 美商Ionis製藥公司 | 用於抑制ｌｐａ的化合物及方法 |
| WO2025082058A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 一种抑制LPA基因表达的dsRNA及其用途 |
| CN120344664A (zh) * | 2023-10-27 | 2025-07-18 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| CN120020252A (zh) * | 2023-11-17 | 2025-05-20 | 纳肽得(青岛)生物医药有限公司 | 抑制LPA表达的siRNA及其用途 |
| WO2025117709A2 (en) * | 2023-11-29 | 2025-06-05 | Sanegene Bio Usa Inc. | Small interfering rna targeting lp(a) and uses thereof |
| CN120098993A (zh) * | 2023-12-05 | 2025-06-06 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
| WO2025170868A1 (en) * | 2024-02-05 | 2025-08-14 | Sirius Therapeutics, Inc. | Polynucleic acid molecules for inhibiting expression of lp(a) or apoc3, pharmaceutical compositions, and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| ATE227342T1 (de) | 1993-09-02 | 2002-11-15 | Ribozyme Pharm Inc | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| JP2005508196A (ja) | 2001-11-07 | 2005-03-31 | アプレラ コーポレイション | 核酸分析の汎用ヌクレオチド |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US20090018097A1 (en) | 2005-09-02 | 2009-01-15 | Mdrna, Inc | Modification of double-stranded ribonucleic acid molecules |
| PT2341943T (pt) | 2008-09-22 | 2019-02-06 | Dicerna Pharmaceuticals Inc | Composições e métodos para a inibição específica de expressão génica por dsrna que possui modificações |
| EP3067359A1 (en) | 2008-09-23 | 2016-09-14 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| HK1201555A1 (en) | 2011-10-25 | 2015-09-04 | Isis Pharmaceuticals, Inc. | Antisense modulation of gccr expression |
| WO2014088920A1 (en) | 2012-12-06 | 2014-06-12 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| WO2015188197A2 (en) | 2014-06-06 | 2015-12-10 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| DK3234132T3 (da) | 2014-12-15 | 2019-08-26 | Dicerna Pharmaceuticals Inc | Ligand-modificerede dobbeltstrengede nukleinsyrer |
| JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| EP3506909B1 (en) | 2016-09-02 | 2022-06-29 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
| MX2020004897A (es) | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| UY38003A (es) | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| US20230078200A1 (en) * | 2019-12-09 | 2023-03-16 | Amgen Inc. | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION |
| KR20250077604A (ko) | 2020-08-05 | 2025-05-30 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
-
2021
- 2021-08-05 KR KR1020257016689A patent/KR20250077604A/ko active Pending
- 2021-08-05 TW TW110128888A patent/TWI886314B/zh active
- 2021-08-05 CN CN202180058046.7A patent/CN116323943A/zh active Pending
- 2021-08-05 EP EP21762318.0A patent/EP4192954A1/en active Pending
- 2021-08-05 IL IL300338A patent/IL300338A/en unknown
- 2021-08-05 TW TW114118397A patent/TW202535432A/zh unknown
- 2021-08-05 CA CA3185348A patent/CA3185348A1/en active Pending
- 2021-08-05 MX MX2023001538A patent/MX2023001538A/es unknown
- 2021-08-05 US US18/040,302 patent/US12435336B2/en active Active
- 2021-08-05 KR KR1020237006019A patent/KR102812602B1/ko active Active
- 2021-08-05 AU AU2021320550A patent/AU2021320550B2/en active Active
- 2021-08-05 WO PCT/US2021/071109 patent/WO2022032288A1/en not_active Ceased
- 2021-08-05 JP JP2023507767A patent/JP7476422B2/ja active Active
- 2021-08-05 BR BR112023001957A patent/BR112023001957A2/pt unknown
-
2024
- 2024-03-07 JP JP2024034617A patent/JP2024081668A/ja active Pending
- 2024-08-16 US US18/807,591 patent/US12252691B2/en active Active
-
2025
- 2025-10-17 AU AU2025252633A patent/AU2025252633A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024081668A5 (enExample) | ||
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JPWO2022032288A5 (enExample) | ||
| JPWO2019183164A5 (enExample) | ||
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| TW202024324A (zh) | 用於抑制17β-HSD第13型(HSD17B13)表現之RNAi藥劑、其組合物及使用方法 | |
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| JP2020529197A5 (enExample) | ||
| JP2018529732A5 (enExample) | ||
| TW202113079A (zh) | 經修飾之間隙子寡核苷酸及其使用方法 | |
| EP1141278B1 (en) | Therapeutic pde4d phosphodiesterase inhibitors | |
| JP2024109582A (ja) | トリループを含む二本鎖核酸インヒビター分子 | |
| JPWO2020061177A5 (enExample) | ||
| JPWO2020132227A5 (enExample) | ||
| JPWO2021188795A5 (enExample) | ||
| JP2021520355A (ja) | Ｔｍ上昇ヌクレオチドで修飾された二本鎖核酸阻害剤分子 | |
| JP2022530678A (ja) | 短縮センス鎖を有する二本鎖核酸阻害剤分子 | |
| JPWO2022031847A5 (enExample) | ||
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| JPWO2022221430A5 (enExample) | ||
| JPWO2022218941A5 (enExample) | ||
| JPWO2021252649A5 (enExample) | ||
| KR20240101580A (ko) | Hbv 치료를 위한 약학 조합물 | |
| TW202345861A (zh) | 經修飾之間隔體寡聚物及其使用方法 |